JPMorgan: Buy into the biotech bear market

Biotech research
Pedro Castellano | Getty Images

The biotech sector plunged 13 percent last week sparked by Hillary Clinton's comments on high drug pricing and her plan for greater regulation of the sector.

Investors are wondering what's next for life sciences stocks as they are now in bear market territory, down 22 percent from July's highs.

JPMorgan reached out to fund managers to find out their current concerns and analyze the prospects for the biotech sector.

Here are the key takeaways in its note to clients sent Monday.

Contact Investing


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about our products and service. Privacy Policy.